You searched for "bladder’"
Urinary biomarkers for surveillance of non-muscle invasive bladder cancer
Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...Action Bladder Cancer UK launches learning module for primary care
Action Bladder Cancer UK has launched a new online learning module for primary care, to help healthcare professionals improve their knowledge of bladder cancer. Bladder cancer is not a rare cancer. In the UK alone, over 23,000 people are diagnosed...Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...
Secondary bladder cancer following upper tract urothelial cancer
Upper tract urothelial carcinoma (UTUC) comprises <5% of all urothelial cancers. A certain proportion of patients with UTUC will develop secondary bladder urothelial cancer (BUC). This paper has retrospectively examined records obtained from several cancer USA population-based registries of more...
The importance of second-look transurethral resection for superficial bladder cancer
This was a prospective study of 100 consecutive patients with a newly diagnosed superficial bladder tumour who underwent a second look transurethral resection of bladder tumour (TURBT) two to six weeks post initial resection. This essentially included pTa multiple and...
BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy
Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...
Repeat transurethral resection in non-muscle invasive bladder cancer
The authors felt this is a big problem because there is no standardised practice on re-resection following initial transurethral resection of bladder tumour (TURBT). Getting detrusor muscle in the first specimen is thought to be important. However muscle is not...
TPTNS: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder
This is a prospective study evaluating the tolerability and efficacy of transcutaneous posterior tibial nerve stimulation (TPTNS) in patients with urodynamically proven overactive bladder (OAB), who have failed anticholinergic treatment. Forty-three patients were studied and followed up over a period...
Needs of children with a chronic bladder in preparation for transfer to adult care
It is well recognised that transition from paediatric to adult practice is stressful for patients and parents. This paper describes a questionnaire-based study of 80 teenagers with chronic bladder disease (spina bifida exstrophy or other acquired neurogenic bladder condition) of...ICS updates on continence care: making sense of detrusor underactivity and the underactive bladder
Countless epidemiological studies have established the frequent occurrence of lower urinary tract symptoms (LUTS) and the significant burden these symptoms incur. For the most part of the past three decades, there has been an overwhelming focus on detrusor overactivity (DO)...
Transurethral en bloc resection versus standard resection of bladder tumour
Bladder cancer is a common urological malignancy, with around 610,000 new cases and 220,000 deaths worldwide in 2022. Approximately 75% of these cases are non-muscle-invasive bladder cancer (NMIBC). The conventional method for treating NMIBC is standard resection (SR), performed transurethrally,...
